ヨーロッパの炭疽菌治療市場、タイプ別（皮膚炭疽菌、肺炭疽菌、腸炭疽菌）、投与経路別（経口、非経口、その他）、エンドユーザー別（政府機関、病院、学術研究機関、その他）業界動向および2029年までの予測。
ヨーロッパ炭疽菌治療市場の分析と洞察
ヨーロッパの炭疽菌治療市場は、細菌感染の発生率の上昇、研究資金の増加、炭疽菌治療の新しい治療法の開発、パイプライン製品による需要の高まり、研究開発への投資の増加などの要因によって牽引されており、市場の成長につながっています。現在、先進国と新興国全体で医療費が増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性が生まれると予想されています。
炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加は、市場にさらなる影響を与えています。ただし、治療と手順に関連する高コスト、および製品承認に関する厳格な政府規制が、炭疽菌治療市場の成長を妨げると予想されます。
ヨーロッパ炭疽菌治療市場レポートは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細を提供し、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点からの機会を分析します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。
ヨーロッパの炭疽菌治療市場は支持的であり、病気の進行を抑えることを目指しています。データブリッジマーケットリサーチは、ヨーロッパの炭疽菌治療市場は2022年から2029年の予測期間中に5.7%のCAGRで成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019 - 2014 にカスタマイズ可能) |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
タイプ別（皮膚炭疽、肺炭疽、腸炭疽）、投与経路別（経口、非経口、その他）、エンドユーザー別（政府機関、病院、学術研究機関、その他）業界動向と2029年までの予測 |
|
対象国 |
ドイツ、フランス、イタリア、イギリス、スペイン、オランダ、ロシア、スイス、トルコ、ベルギー、その他のヨーロッパ諸国 |
|
対象となる市場プレーヤー |
Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、EMERGENT、Sanofi、Porton Biopharma、Lupin、Soligenix、武田薬品工業株式会社、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited、INDOCO REMEDIES LTD.、DEINOVE など |
ヨーロッパ炭疽菌治療市場の動向
市場の定義
炭疽病は、炭疽菌 (B. anthracis) と呼ばれる細菌によって引き起こされます。これは主に、土壌中の胞子を摂取することで感染する家畜の病気です。人間は通常、皮革や羊毛などの感染した動物の製品を扱ったり、感染した動物製品から炭疽菌の胞子を吸い込んだりすることで炭疽病に感染します。感染した動物の肉を調理が不十分な状態で食べることでも感染することがあります。炭疽病が人から人へ感染することは知られていません。
炭疽菌感染症には 3 つの臨床的形態があります。皮膚炭疽菌感染症が最も一般的で、報告された症例の 95% 以上を占めています。皮膚炭疽菌感染症は、皮膚の擦り傷から胞子が侵入することで発生し、世界中で毎年 2,000 件発生していると推定されています。
炭疽菌の鑑別診断には、臨床的特徴に応じて、PCR、グラム染色、血液、胸水、潰瘍部位、脳脊髄液、および便からの培養などの関連検体が含まれます。利用可能な技術は多数あります。ほとんどの検査は、培養ベースの従来の方法、免疫学的検出、核酸ベースの検査、リガンドベースの検出、およびバイオセンサーのいずれかの技術を使用して、微生物全体、微生物抗原、または微生物核酸を検出することに基づいています。
ドライバー
- 炭疽菌感染症の蔓延
細菌感染症の発生は世界中で増加しています。炭疽は、好気性グラム陽性胞子形成細菌である炭疽菌によって引き起こされる細菌感染症です。炭疽菌胞子の侵入経路に応じて、主に皮膚、肺、または胃腸の感染症として発生します。後に、特徴的な黒いかさぶた状の斑点が患部の皮膚に現れ、数週間後には緩み始め、最終的に剥がれ落ちて瘢痕を残します。これらの経過は非常に特徴的であるため、まれではありますが、この病気に精通している医師が診断を見逃すことはほとんどありません。肺炭疽は、3 種類の炭疽の中で最も致命的で、吸入された胞子が気管気管支リンパ節内で発芽して増殖します。炭疽は、人間と動物の両方に影響を与える有害な病気です。これは炭疽菌によって引き起こされる生命を脅かす感染症です。炭疽菌感染症の発生率と蔓延が増加しているため、少量の感染でも検出できる感度の高い診断アプローチの必要性が高まっています。
炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加が、市場にさらなる影響を与えています。
- 炭疽菌治療対象者に対する研究資金の増加と新しい治療法の開発
さまざまなタイプの患者を治療するための手順を変更するには、研究開発が必須条件です。炭疽菌治療の需要は、すべての国を巻き込んで世界中で高まっています。そのため、企業は患者に効果的な治療を提供することに成功するために、研究開発に継続的に注力しています。近年、診断を新たな段階に進める多くの診断アプローチが登場しており、人体中の寄生虫の最小量さえも検出できるものが多くあります。
診断におけるこれらの新しいアプローチは、市場を前進させるでしょう。研究資金の増加と炭疽菌治療のための新しい治療法の開発により、炭疽菌に対して効果的に作用するために細菌の増殖と毒素生成の両方を標的とする、いくつかの新しい抗生物質と既存の抗生物質、および有望性が高まっている毒素阻害剤があります。
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Europe anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Europe market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the Europe anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
Europe Anthrax Treatment Market Segmentation
Europe anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the Europe anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, Europe anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, Europe anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
The Europe anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and Rest of Europe.
発展途上地域での技術進歩の進展により、ドイツが優位に立つことが予想されます。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税と貿易ルートの影響も考慮されます。
競争環境と炭疽菌治療市場シェア分析
ヨーロッパ炭疽菌治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、ヨーロッパでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、炭疽菌治療市場における会社の重点にのみ関連しています。
市場のプレーヤーとしては、Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、EMERGENT、Sanofi、Porton Biopharma、Lupin、Soligenix、Takeda Pharmaceutical Company Limited、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited、INDOCO REMEDIES LTD.、DEINOVEなどが挙げられます。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、ヨーロッパと地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 EUROPE ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 EUROPE ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 EUROPE ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 EUROPE ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 EUROPE ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 EUROPE VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 RUSSIA
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 BELGIUM
11.1.11 REST OF EUROPE
12 EUROPE ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 EUROPE ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 EUROPE GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 EUROPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 EUROPE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 46 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 47 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 48 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 49 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 52 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 53 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 54 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 55 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 EUROPE VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 EUROPE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 63 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 64 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 67 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 68 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 70 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 EUROPE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 73 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 74 EUROPE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 79 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 82 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 83 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 84 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 85 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 EUROPE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 88 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 89 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 90 EUROPE ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 91 GERMANY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 94 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 95 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 96 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 GERMANY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 99 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 100 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 101 GERMANY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 102 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 103 GERMANY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 106 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 107 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 108 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 109 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 110 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 112 GERMANY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 113 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 114 GERMANY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 115 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 116 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 117 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 118 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 119 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 120 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 121 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 122 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 123 GERMANY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 124 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 125 GERMANY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 126 GERMANY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 127 FRANCE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 129 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 130 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 131 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 132 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 133 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 134 FRANCE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 135 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 136 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 137 FRANCE VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 138 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 139 FRANCE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 140 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 141 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 142 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 143 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 144 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 145 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 146 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 147 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 148 FRANCE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 149 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 150 FRANCE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 151 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 152 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 153 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 154 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 155 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 156 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 157 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 158 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 159 FRANCE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 160 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 161 FRANCE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 162 FRANCE ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 163 U.K. ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 U.K. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 165 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 166 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 167 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 168 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 169 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 170 U.K. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 171 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 172 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 173 U.K. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 174 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 175 U.K. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 176 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 177 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 178 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 179 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 180 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 181 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 182 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 183 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 184 U.K. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 185 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 186 U.K. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 187 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 188 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 189 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 190 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 191 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 192 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 193 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 194 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 195 U.K. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 196 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 197 U.K. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 198 U.K. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 199 ITALY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 ITALY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 201 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 202 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 203 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 204 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 205 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 206 ITALY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 207 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 208 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 209 ITALY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 210 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 211 ITALY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 212 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 213 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 214 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 215 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 216 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 217 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 218 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 219 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 220 ITALY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 221 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 222 ITALY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 223 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 224 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 225 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 226 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 227 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 228 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 229 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 230 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 231 ITALY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 232 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 233 ITALY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 234 ITALY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 235 RUSSIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 RUSSIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 237 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 238 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 239 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 240 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 241 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 242 RUSSIA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 243 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 244 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 245 RUSSIA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 246 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 247 RUSSIA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 248 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 249 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 250 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 251 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 252 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 253 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 254 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 255 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 256 RUSSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 257 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 258 RUSSIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 259 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 260 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 261 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 262 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 263 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 264 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 265 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 266 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 267 RUSSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 268 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 269 RUSSIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 270 RUSSIA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 271 SPAIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 SPAIN CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 273 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 274 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 275 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 276 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 277 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 278 SPAIN BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 279 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 280 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 281 SPAIN VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 282 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 283 SPAIN PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 284 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 285 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 286 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 287 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 288 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 289 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 290 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 291 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 292 SPAIN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 293 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 294 SPAIN INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 295 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 296 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 297 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 298 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 299 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 300 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 301 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 302 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 303 SPAIN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 304 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 305 SPAIN ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 306 SPAIN ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 307 TURKEY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 308 TURKEY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 309 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 310 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 311 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 312 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 313 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 314 TURKEY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 315 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 316 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 317 TURKEY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 318 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 319 TURKEY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 320 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 321 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 322 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 323 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 324 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 325 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 326 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 327 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 328 TURKEY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 329 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 330 TURKEY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 331 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 332 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 333 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 334 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 335 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 336 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 337 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 338 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 339 TURKEY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 340 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 341 TURKEY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 342 TURKEY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 343 NETHERLANDS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 344 NETHERLANDS CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 345 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 346 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 347 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 348 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 349 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 350 NETHERLANDS BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 351 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 352 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 353 NETHERLANDS VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 354 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 355 NETHERLANDS PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 356 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 357 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 358 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 359 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 360 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 361 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 362 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 363 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 364 NETHERLANDS VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 365 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 366 NETHERLANDS INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 367 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 368 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 369 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 370 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 371 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 372 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 373 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 374 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 375 NETHERLANDS VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 376 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 377 NETHERLANDS ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 378 NETHERLANDS ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 379 SWITZERLAND ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 381 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 382 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 383 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 384 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 385 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 386 SWITZERLAND BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 387 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 388 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 389 SWITZERLAND VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 390 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 391 SWITZERLAND PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 392 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 393 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 394 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 395 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 396 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 397 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 398 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 399 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 400 SWITZERLAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 401 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 402 SWITZERLAND INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 403 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 404 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 405 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 406 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 407 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 408 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 409 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 410 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 411 SWITZERLAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 412 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 413 SWITZERLAND ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 414 SWITZERLAND ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 415 BELGIUM ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 416 BELGIUM CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 417 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 418 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 419 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 420 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 421 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 422 BELGIUM BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 423 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 424 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 425 BELGIUM VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 426 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 427 BELGIUM PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 428 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 429 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 430 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 431 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 432 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 433 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 434 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 435 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 436 BELGIUM VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 437 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 438 BELGIUM INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 439 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 440 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 441 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 442 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 443 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 444 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 445 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 446 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 447 BELGIUM VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 448 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 449 BELGIUM ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 450 BELGIUM ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 451 REST OF EUROPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 EUROPE ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE EUROPE ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 EUROPE DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE ANTHRAX TREATMENT MARKET
FIGURE 21 EUROPE ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 EUROPE ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 EUROPE ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 EUROPE ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 EUROPE ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 EUROPE ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 EUROPE ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
